Compare Abeona Therapeutics Inc (ABEO) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Synopsys, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Synopsys, Inc. trades at $433.3 (market cap $83.61B). The key difference: Synopsys, Inc. is far larger — about 224× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Synopsys, Inc. nearer its low. Which is the better fit depends on your goals.
| ABEO | SNPS | |
|---|---|---|
Market Cap | $373.32M | $83.61B |
Sector | Health | Technology |
52-Week High | $7.23 | $645.59 |
52-Week Low | $4.17 | $380.47 |
Enterprise Value | $228.22M | $91.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Synopsys (SNPS) trades at $436.63, down 0.12% on the day, with a bearish technical signal despite strong analyst support. The stock shows consistent earnings beats, with Q1 2026 EPS of $3.35 exceeding expectations, and maintains robust gross margins of 73.47%. Recent news highlights the company's strategic pivot toward AI-driven design tools, though cash flow trends show volatility with a net outflow of $1.01B in 2025.
Outlook remains positive with a consensus price target of $558.33 implying 28% upside, driven by AI adoption and market positioning. Key risks include high valuation multiples (P/E of 101.21) and execution challenges in shifting business focus. Investors should weigh growth potential against premium pricing and competitive pressures in the semiconductor software space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
